CTLA4 and glioblastoma: Immune checkpoint inhibitors (ICIs) with anti-PD-1 and anti-CTLA4 have radically changed the treatment of many other tumour types but have not demonstrated a survival advantage in GBM thus far [7,8]; however, further evaluation is ongoing, with neoadjuvant ICI showing promising initial results [9,10].